4 results on atopic dermatitis
To assess the safety and efficacy of DBV712 in initiating desensitisation of peanut in children aged 1 to 3 years with peanut allergy, after 12 months of treatment with Epicutaneous Immunotherapy EPIT).
The objectives of this follow-up study of the EPITOPE study are:• To assess the clinical benefit of Viaskin Peanut after up to 3 years of epicutaneous immunotherapy (EPIT) to induce/maintain desensitization to peanut in peanut-allergic children;• To…
The primary objective of the trial is to assess a non-flat dose-response curve and to evaluate the dose-response relationship for 3 oral dose regimens of BI 1291583 versus placebo, on the primary endpoint, time to first pulmonary exacerbation up to…
Primary• To evaluate the safety and tolerability of single ascending IV doses of ANX105 in normal healthy participantsSecondary• To characterize the single-dose PD of ANX105• To characterize the single-dose PK of ANX105